Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sunshine Biopharma (NASDAQ: SBFM) reported significant progress for the fiscal year ending December 31, 2022. Key highlights include a cash position of $21 million and a revenue surge from $228,426 in 2021 to $4,345,603 in 2022, largely due to the acquisition of Nora Pharma Inc., which added 49 prescription drugs to their portfolio. The company is advancing its proprietary drug development programs, collaborating with the University of Arizona on COVID-19 treatment and progressing the K1.1 mRNA anticancer initiative. Sunshine Biopharma plans to increase its offerings to 86 generic pharmaceuticals over the next two years.
Sunshine Biopharma (NASDAQ: SBFM) announced a worldwide exclusive license agreement with the University of Arizona for technology related to PLpro protease inhibitors targeting SARS-CoV-2. This collaboration, which began in February 2022, aims to enhance the fight against COVID-19 by providing an additional treatment option beyond existing therapies like Paxlovid®. The licensed technology includes small molecules that inhibit PLpro, essential for the virus's pathogenicity. The agreement marks a significant milestone in Sunshine Biopharma's COVID-19 treatment pipeline, which also includes various cancer therapies.